Investigators find that the normalized mean ESA dose decreases as patients' elevation of residence increases.
Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin.
New findings implicate transferrin saturation and nutritional status assessed by albumin.
After 54 weeks of treatment with testosterone undecanoate, anemia prevalence decreased from 29.6% to 10%.
A summary of Dr. Jeffrey S. Berns' presentation that will be given at the National Kidney Foundation's 2016 Spring Clinical Meetings in Boston, MA.
Trend is independent of intravenous iron use and exposure to erythropoiesis-stimulating agents.
No new adverse events observed in patients with underlying cardiovascular risk factors who switched to continuous erythropoietin receptor activator.
Greater hyporesponsiveness to erythropoiesis-stimulating agents was associated with increased PLR ratios.
Observed rates of all-cause and cardiovascular mortality and myocardial infarction were consistent with expected rates, study shows.
Researchers observe significantly higher levels of albumin and hemoglobin and better calcium and phosphate metabolism.
Based on effect of erythropoietin-stimulating agents for higher hemoglobin targets.
In a phase 2 trial, roxadustat maintained hemoglobin levels over 19 weeks as well as epoetin alfa.
In a case-control study, the treatment did not adversely affect mortality or recovery from AKI.
Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients.
Treatment corrects anemia and improves quality of life, according to a systemic review.
Six-months of supplementation has no impact on epoetin utilization in HD patients with low 25(OH)D.
In a study, investigators observed that levels were higher in those with stage 3a than stage 3b chronic kidney disease.
The estimated potential staff time savings totaled 23 hours for an average facility with 70 patients, researchers found.
Rates of death and important non-fatal outcomes between ferumoxytol and iron sucrose or sodium ferric gluconate do not differ significantly.
For ICU patients, hemoglobin level thresholds vary with presence of comorbid heart disease.
Risk of anaphylaxis associated with IV iron highest for iron dextran, lowest for iron sucrose.
Having hemoglobin 9-11 g/dL prior to dialysis provided the best life expectancy.
It is unclear whether RDW is a risk factor for early death or a byproduct of biological and metabolic imbalances.
Patients prescribed the lipid-lowering agents were less likely to exhibit hyporesponsiveness to the medications.
Study finds no gender differences in parathyroid hormone, ferritin, Kt/V, or age.
In a study, the mean hemoglobin level increased significantly in hemodialysis patients with functional iron deficiency.
The association is independent of anemia, according to researchers.
Patients with vs. without protein-energy wasting syndrome had a significantly lower mean hemoglobin level.
Hepatitis C viral infection found to increase likelihood of requiring blood transfusions and hemoglobin levels dropping below 8.5 g/dL.
Iron deficiency may contribute to the relationship between proteinuria and excess FGF-23, researchers suggested.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)